Prof. Dr. med. Gunther Hartmann
Institute of Clinical Chemistry & Clinical Pharmacology
gunther.hartmann@ukbonn.de View member: Prof. Dr. med. Gunther Hartmann
EMBO molecular medicine
The utilisation of protein biomarker panels, rather than individual protein biomarkers, offers a more comprehensive representation of human physiology. It thus has the potential to improve diagnosis, prognosis and the differentiation of responders from nonresponders in the context of precision medicine. Although several proteomic techniques exist for measuring biomarker panels, the integration of proteomics into clinical practice has been limited. In this Commentary, we highlight the significance of quantitative protein biomarker panels in clinical medicine and outline the challenges that must be addressed in order to identify the most promising panels and implement them in clinical routines to realise their medical potential. Furthermore, we argue that the absolute quantification of protein panels through targeted mass spectrometric assays remains the most promising technology for translating proteomics into routine clinical applications due to its high flexibility, low sample costs, independence from affinity reagents and low entry barriers for its integration into existing laboratory workflows.
© 2023 The Authors. Published under the terms of the CC BY 4.0 license.
PMID: 36939029
Institute of Clinical Chemistry & Clinical Pharmacology
gunther.hartmann@ukbonn.de View member: Prof. Dr. med. Gunther Hartmann